dentalcorp Holdings Valuation

Is DNTL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DNTL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DNTL (CA$9.35) is trading below our estimate of fair value (CA$29.25)

Significantly Below Fair Value: DNTL is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for DNTL?

Key metric: As DNTL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DNTL. This is calculated by dividing DNTL's market cap by their current revenue.
What is DNTL's PS Ratio?
PS Ratio1.2x
SalesCA$1.51b
Market CapCA$1.75b

Price to Sales Ratio vs Peers

How does DNTL's PS Ratio compare to its peers?

The above table shows the PS ratio for DNTL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
AND Andlauer Healthcare Group
2.6x4.6%CA$1.7b
WELL WELL Health Technologies
1.3x9.3%CA$1.3b
VMD Viemed Healthcare
1.8x17.8%CA$311.8m
CARE Dialogue Health Technologies
3.6x18.8%CA$346.0m
DNTL dentalcorp Holdings
1.2x9.8%CA$1.8b

Price-To-Sales vs Peers: DNTL is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (1.9x).


Price to Sales Ratio vs Industry

How does DNTL's PS Ratio compare vs other companies in the CA Healthcare Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
DOC CloudMD Software & Services
0.1xn/aUS$7.82m
NPTH NeuPath Health
0.1xn/aUS$6.45m
PHA Premier Health of America
0.05x4.3%US$5.56m
BLMH Bloom Health Partners
0.1xn/aUS$2.85m
DNTL 1.2xIndustry Avg. 1.0xNo. of Companies8PS00.61.21.82.43+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DNTL is expensive based on its Price-To-Sales Ratio (1.2x) compared to the North American Healthcare industry average (1x).


Price to Sales Ratio vs Fair Ratio

What is DNTL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DNTL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: DNTL is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DNTL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$9.35
CA$12.13
+29.7%
4.4%CA$13.00CA$11.50n/a6
Nov ’25CA$9.40
CA$11.00
+17.0%
4.9%CA$11.75CA$10.00n/a9
Oct ’25CA$8.44
CA$10.34
+22.5%
14.6%CA$11.50CA$6.10n/a10
Sep ’25CA$7.88
CA$10.34
+31.2%
14.6%CA$11.50CA$6.10n/a10
Aug ’25CA$7.78
CA$10.09
+29.6%
14.2%CA$11.50CA$6.10n/a10
Jul ’25CA$8.24
CA$10.04
+21.8%
14.0%CA$11.50CA$6.10n/a10
Jun ’25CA$6.99
CA$10.04
+43.6%
14.0%CA$11.50CA$6.10n/a10
May ’25CA$6.28
CA$10.05
+60.1%
15.6%CA$11.50CA$6.10n/a11
Apr ’25CA$6.75
CA$10.01
+48.3%
16.3%CA$11.50CA$6.10n/a10
Mar ’25CA$6.77
CA$10.08
+48.9%
16.5%CA$11.50CA$5.80n/a10
Feb ’25CA$6.80
CA$9.88
+45.3%
16.6%CA$11.50CA$5.80n/a10
Jan ’25CA$6.96
CA$10.28
+47.7%
16.1%CA$11.50CA$5.80n/a10
Dec ’24CA$5.63
CA$10.28
+82.6%
16.1%CA$11.50CA$5.80n/a10
Nov ’24CA$5.38
CA$12.05
+124.0%
18.4%CA$15.00CA$6.00CA$9.4010
Oct ’24CA$5.90
CA$12.77
+116.5%
19.0%CA$16.00CA$6.00CA$8.4411
Sep ’24CA$6.90
CA$12.77
+85.1%
19.0%CA$16.00CA$6.00CA$7.8811
Aug ’24CA$8.01
CA$13.60
+69.8%
8.5%CA$16.00CA$12.50CA$7.7810
Jul ’24CA$7.34
CA$13.60
+85.3%
8.5%CA$16.00CA$12.50CA$8.2410
Jun ’24CA$7.04
CA$13.50
+91.8%
8.0%CA$16.00CA$12.50CA$6.999
May ’24CA$8.65
CA$14.28
+65.1%
6.6%CA$16.00CA$13.00CA$6.289
Apr ’24CA$9.00
CA$14.28
+58.6%
6.6%CA$16.00CA$13.00CA$6.759
Mar ’24CA$9.45
CA$14.67
+55.2%
5.1%CA$16.00CA$13.50CA$6.779
Feb ’24CA$9.71
CA$14.70
+51.4%
4.9%CA$16.00CA$13.50CA$6.8010
Jan ’24CA$8.90
CA$14.70
+65.2%
4.9%CA$16.00CA$13.50CA$6.9610
Dec ’23CA$8.43
CA$14.70
+74.4%
4.9%CA$16.00CA$13.50CA$5.6310
Nov ’23CA$7.80
CA$16.55
+112.1%
5.4%CA$18.00CA$15.50CA$5.3811

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies